49
Participants
Start Date
October 6, 2016
Primary Completion Date
March 17, 2021
Study Completion Date
June 30, 2021
DNX-2401
On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
pembrolizumab
Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
Memorial Sloan Kettering Cancer Center, New York
Weill-Cornell Medicine New York-Presbyterian, New York
Lehigh Valley Health Network, Allentown
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Ohio State University James Cancer Center, Columbus
Cleveland Clinic, Cleveland
University of Minnesota Neurosurgery, Minneapolis
Northwestern University, Chicago
University of Arkansas for Medical Sciences (UAMS), Little Rock
MD Anderson Cancer Center, Houston
Texas Oncology Austin-Midtown, Austin
Huntsman Cancer Institute, Salt Lake City
UCLA Medical Center, Los Angeles
Rutgers Cancer Institute of New Jersey, New Brunswick
University Health Network, Toronto
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
DNAtrix, Inc.
INDUSTRY